Gilead Sciences to acquire small molecule oral STAT6 from LEO Pharma for $1.7bn.

Gilead Sciences, a biopharmaceutical company, agreed to acquire small molecule oral STAT6 from LEO Pharma, a pharmaceutical company, for $1.7bn. “STAT6 holds potential for treating various inflammatory diseases, including outside dermatology. This strategic partnership with Gilead will enable us to accelerate the development of the STAT6 program and maximize its potential in dermatology and beyond. This partnership acknowledges LEO Pharma’s scientific capabilities and strengthens our commitment to innovate for people with skin diseases,” Christophe Bourdon, LEO Pharma CEO.